ASML Holding N.V. — 2014 Form 20-F
Reporting period: Fiscal year ended December 31, 2014. Although the request refers to 2014 Q4, this filing is an annual report and does not provide a clear standalone set of fourth-quarter financial results. Financial figures below are in euros unless stated otherwise.
Business context and reporting period
ASML develops, manufactures and services lithography, metrology and software systems used by semiconductor manufacturers. Its results depend on cyclical customer spending and continued advances in chipmaking technology. The financial statements are prepared under U.S. GAAP. Cymer, acquired in May 2013, is included for the full year in 2014 versus seven months in 2013.
Key financial metrics
| Metric | 2014 | 2013 |
|---|---|---|
| Net sales | €5.856 billion | €5.245 billion |
| Gross profit / margin | €2.596 billion / 44.3% | €2.177 billion / 41.5% |
| Operating income / margin | €1.282 billion / 21.9% | €1.048 billion / 20.0% |
| Net income / margin | €1.197 billion / 20.4% | €1.015 billion / 19.4% |
| Basic earnings per share | €2.74 | €2.36 |
| Operating cash flow | €1.025 billion | €1.054 billion |
| PP&E purchases | €358 million | €211 million |
| Cash and cash equivalents at year-end | €2.419 billion | €2.331 billion |
| Short-term investments at year-end | €335 million | €680 million |
| Long-term debt, including current portion | €1.154 billion | €1.075 billion |
| Working capital | €4.257 billion | €4.157 billion |
Cash and short-term investments totaled approximately €2.754 billion at year-end, exceeding reported debt by approximately €1.600 billion. Operating cash flow less PP&E purchases was approximately €667 million; this is a simple calculation, not a company-reported free-cash-flow measure. The €700 million revolving credit facility was undrawn, matures in 2018, and its covenant was met.
Material changes versus the prior comparable period
- Revenue rose 11.6%; service and field-option sales increased 28.9% to €1.614 billion, while system sales rose 6.3% to €4.243 billion.
- ASML sold 136 systems, down from 157, but average selling price per system increased to €31.2 million from €25.4 million, reflecting a higher-end product mix. The company attributed higher service sales partly to the full-year inclusion of Cymer and growth in Holistic Lithography.
- Gross margin improved 2.8 percentage points. Management cited Cymer’s full-year contribution, higher Holistic Lithography sales and lower one-off Cymer purchase-accounting adjustments; higher EUV sales partly offset the improvement because EUV systems did not then contribute to gross profit.
- R&D costs increased 21.8% to €1.074 billion, mainly due to accelerated EUV and next-generation immersion programs. Customer co-investment program (CCIP) contributions recognized as other income were €81 million, versus €64 million.
- Operating cash flow was slightly lower, which management linked mainly to higher working capital and lower accounts payable. Capital expenditures increased to €358 million, primarily for EUV production facilities.
- The effective tax rate rose to 6.0% from 0.8%, but remained low; management cited tax settlements relating to pre-acquisition ASML Netherlands and Cymer agreements. The 2013 rate was affected by a non-taxable Cymer acquisition-accounting gain.
- Systems backlog increased to 82 systems valued at €2.772 billion from 56 systems valued at €1.953 billion. The 2014 backlog definition newly included two NXE:3350B EUV systems; the filing says the change did not affect comparative figures.
Outlook, risks, contingencies and unusual items
- Near-term outlook: For Q1 2015, ASML expected net sales of about €1.6 billion, gross margin of about 47%, R&D costs of about €260 million, other income of about €20 million and SG&A costs of about €83 million. For the first half of 2015, it expected strong Memory sales and service/field-option business, with Logic sales increasing from the second half of 2014.
- EUV execution: ASML reported achieving customer-set productivity of 500 wafers per day and described 1,000 wafers per day as its 2015 target. It targeted 1,500 wafers per day in 2016. Further adoption depends on source power, availability, performance, customer acceptance and supplier development; delays or competing technologies could impair expected returns on R&D and supplier advances.
- Investment and capital returns: 2015 capital expenditures were expected to be approximately €410 million, mainly for EUV capacity. A proposed 2014 dividend of €0.70 per share required AGM approval. A 2015–2016 buyback program announced in January 2015 contemplated up to €750 million of shares for cancellation plus up to 3.3 million shares for employee plans.
- Principal business risks: Semiconductor-industry cyclicality; concentrated customer exposure; reliance on Zeiss as the sole supplier of critical optics; technology-development and product-ramp risks; foreign-exchange exposure; and dependence on a limited number of manufacturing sites. One customer represented 26.2% of 2014 sales, down from 39.2%; the three largest customers represented 49.3% of receivables and finance receivables at year-end.
- Legal and contractual items: The filing records €12.9 million of estimated legal losses in 2014. From January 2015, ASML and Nikon could bring certain patent claims under their cross-license arrangements, including claims related to 2010–2014; the filing says outcomes and whether litigation would occur were uncertain. Contractual obligations totaled €3.073 billion, including €1.589 billion of purchase obligations, largely due within one year; many supplier commitments permit delay or cancellation subject to contract terms.
- Other notable matters: The CCIP participants held approximately 22.3% of outstanding shares at year-end, with transfer restrictions and possible future sales. Development of 450mm lithography systems remained paused pending clearer customer demand. Management reported effective disclosure controls and internal control over financial reporting; Deloitte issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether EUV productivity and source-performance milestones were achieved on schedule, and whether EUV systems can reach commercially viable gross margins.
- Whether the Q1 2015 sales and margin outlook, 2015 capital-spending plan and EUV shipment plans were subsequently met.
- How much of 2014’s margin and earnings improvement was sustainable versus product mix, Cymer consolidation, purchase-accounting effects and unusually low taxes.
- Whether backlog converts to revenue as expected, given customer rescheduling or cancellation rights and the updated backlog definition.
- Customer concentration, receivables exposure and any change in major customer orders or CCIP shareholder selling activity.
- Potential Nikon patent disputes, the €12.9 million legal-loss estimate and material supplier commitments or advance payments, particularly those tied to EUV.